Abstract: AIM: To investigate the effect and mechanism of recombinant human endostatin (endostar) in therapy malignant ascites in mice.METHODS: Mouse models bearing ascites tumors were established via intraperitoneal injection of H22 cell lines.120 ICR mice were randomly divided into 5 groups and recieved intraperitoneal injection once a day for five(cisplatin)or six(endoustar) days: control(0.9% normal saline),endostar group1(8 mg/kg), endostar group2 (8 mg/kg, received injection after H22 cell line injection 24 hours),combined group (endostar 8 mg/kg plus cisplatin 1 mg/kg), cisplatin group (1 mg/kg). Besides the endostar group2, all groups received intraperitoneal injection at the sixth day after mouse model established .Weight, volume of ascites ,life span and adverse reaction in each group were recorded respectively.The levels of Evan's blue dye in the ascites fluid were assayed to determine the mouse peritoneal microvascular permeability.The levels of VEGF, MMP-2 in serum and ascites fluid were determined by ELISA assay.RESULTS: Compared with control group, all treatment groups could reduce the peritoneal ascites fluid,prolong the life span, decrease the peritoneal microvascular permeability and levels of VEGF, MMP-2 in serum and ascites fluid (P<0.05),and the combined group is more obviously.CONCLUSION: Endostar combined with cisplatin could improve the efficacy because it significantly decreases the levels of VEGF, MMP-2 in serum and ascites fluid.

Key words: recombinant human endostatin, cisplatin, H22 cell ascites tumor, vascular endothelial growth factor(VEGF), matrix metalloproteinase-2(MMP-2)